share_log

Arcutis Biotherapeutics | 8-K: Current report

SEC ·  Jun 19 04:53

Summary by Moomoo AI

On June 14, 2024, Arcutis Biotherapeutics, Inc. conducted its 2024 Annual Meeting of Stockholders, where three key proposals were voted upon. The proposals, detailed in the Company's definitive proxy statement filed on April 26, 2024, included the election of three Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of the compensation of the Company's named executive officers on a non-binding advisory basis. Stockholders of record as of April 22, 2024, were eligible to vote, with 115,524,989 shares outstanding at the time. All proposals were approved, with Terrie Curran, Halley Gilbert, and Keith R. Leonard, Jr. being elected as directors. The selection of Ernst & Young LLP was ratified with an overwhelming majority, and the executive compensation was also approved, albeit with a notable number of votes against.
On June 14, 2024, Arcutis Biotherapeutics, Inc. conducted its 2024 Annual Meeting of Stockholders, where three key proposals were voted upon. The proposals, detailed in the Company's definitive proxy statement filed on April 26, 2024, included the election of three Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of the compensation of the Company's named executive officers on a non-binding advisory basis. Stockholders of record as of April 22, 2024, were eligible to vote, with 115,524,989 shares outstanding at the time. All proposals were approved, with Terrie Curran, Halley Gilbert, and Keith R. Leonard, Jr. being elected as directors. The selection of Ernst & Young LLP was ratified with an overwhelming majority, and the executive compensation was also approved, albeit with a notable number of votes against.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more